A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

This study has been withdrawn prior to recruitment.

( Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data. )

Study NCT00060554 Information provided by Schering-Plough

First Received: May 7, 2003 Last Updated: November 2, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

fondaparinux sodium
heparin

Additional drug interventions recognized in this trial

Fondaparinux
Org 31540

More general drug interventions related to this trial

Sponsors listed in this trial

Schering-Plough